# Intratumoral N17350 in Advanced Solid Tumors

Source: https://onco.cc/trials/nct07339176/  
OnCo record `nct07339176` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of N17350 in melanoma, head and neck squamous cell carcinoma and non-small-cell lung cancer, run by Onchilles Pharma Inc, now recruiting.

## Summary

Intratumoral N17350 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07339176 by Onchilles Pharma Inc, with 275 participants planned, started 2026-05-25 and due to reach its primary completion in 2028-07. Interventions recorded: N17350.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07339176
- Phase: 1/2
- Setting: A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors
- Sponsor: Onchilles Pharma Inc
- Enrolled: 275

## Sources

- ClinicalTrials.gov NCT07339176: https://clinicaltrials.gov/study/NCT07339176

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct07339176.json